Compare Berkshire Hathaway Inc Class B (BRK.B) vs Gilead Sciences, Inc. (GILD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Berkshire Hathaway Inc Class B vs Gilead Sciences, Inc. — how do they compare? Berkshire Hathaway Inc Class B trades at $488.65, while Gilead Sciences, Inc. trades at $131.62 (market cap $161.45B). The key difference: Gilead Sciences, Inc. pays a 2.52% dividend while Berkshire Hathaway Inc Class B pays none. Which is the better fit depends on your goals.
| BRK.B | GILD | |
|---|---|---|
Sector | Financials | Health |
52-Week High | $513.70 | $155.80 |
52-Week Low | $459.10 | $108.22 |
Market Cap | — | $161.45B |
Enterprise Value | — | $175.98B |
Dividend Yield | — | 2.52% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BRK.B trades at $488.5, down 1.67% today, with technical indicators showing a bullish trend from moving averages but neutral oscillators. Support levels are near $483-$489, while resistance sits at $495-$501. Analyst consensus is positive with 57% buy ratings, though key financial ratios are not provided in the current data.
The outlook remains cautiously optimistic due to strong analyst support and technical bullish signals, but risks include market volatility and reliance on broader economic conditions. Investors should monitor upcoming earnings for fundamental clarity amid missing valuation metrics.
Gilead Sciences (GILD) trades at $131.40, up 1.21% with strong technical momentum and bullish moving averages. The company demonstrates robust fundamentals with a 30.99% net income margin and consistent earnings beats in recent quarters. Recent FDA approvals for Trodelvy in metastatic triple-negative breast cancer and ongoing Ebola antiviral trials highlight pipeline strength. Analyst consensus remains strongly positive with a $152.83 price target.
GILD presents a compelling investment case with strong profitability, expanding oncology portfolio, and 67% analyst buy ratings. Key risks include patent expirations on HIV drugs and volatile cash flow trends. The stock offers 16% upside to consensus target with dividend support, though investors should monitor pipeline execution and generic competition timelines.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Berkshire Hathaway Inc Class B
Berkshire Hathaway is a holding company with diverse subsidiaries, primarily in insurance through Geico and its reinsurance groups. It reinvests profits into various industries, owning Burlington Northern Santa Fe (railroad), Berkshire Hathaway Energy, and major manufacturing, service, and retail businesses like Precision Castparts and Lubrizol. The company operates in a highly decentralized manner.
Read more on BRK.B →About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →
